Multimodally profiling memory T cells from a tuberculosis cohort identifies cell state associations with demographics, environment and disease
Multimodal T cell profiling can enable more precise characterization of elusive cell states underlying disease. Here, we integrated single-cell RNA and surface protein data from 500,089 memory T cells to define 31 cell states from 259 individuals in a Peruvian tuberculosis (TB) progression cohort. A...
Gespeichert in:
Veröffentlicht in: | Nature immunology 2021-06, Vol.22 (6), p.781-793 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Multimodal T cell profiling can enable more precise characterization of elusive cell states underlying disease. Here, we integrated single-cell RNA and surface protein data from 500,089 memory T cells to define 31 cell states from 259 individuals in a Peruvian tuberculosis (TB) progression cohort. At immune steady state >4 years after infection and disease resolution, we found that, after accounting for significant effects of age, sex, season and genetic ancestry on T cell composition, a polyfunctional type 17 helper T (T
H
17) cell–like effector state was reduced in abundance and function in individuals who previously progressed from
Mycobacterium tuberculosis
(
M.tb
) infection to active TB disease. These cells are capable of responding to
M.tb
peptides. Deconvoluting this state—uniquely identifiable with multimodal analysis—from public data demonstrated that its depletion may precede and persist beyond active disease. Our study demonstrates the power of integrative multimodal single-cell profiling to define cell states relevant to disease and other traits.
Raychaudhuri and colleagues use high-dimensional single-cell analysis of T cells from a human tuberculosis progression cohort. They identify a T
H
17–like cluster reactive to
Mycobacterium tuberculosis
peptides that is reduced in people who previously progressed to active disease. |
---|---|
ISSN: | 1529-2908 1529-2916 |
DOI: | 10.1038/s41590-021-00933-1 |